144 related articles for article (PubMed ID: 11957787)
1. [Measurement of outpatient treatment costs of chronic inflammatory bowel diseases at a German university hospital].
Rösch M; Leidl R; Thomas S; von Tirpitz C; Reinshagen M; Adler G; König HH
Med Klin (Munich); 2002 Mar; 97(3):128-36. PubMed ID: 11957787
[TBL] [Abstract][Full Text] [Related]
2. [Costs of ambulant care for patients with inflammatory bowel disease in general practice].
Beiche A; König HH; Ebinger M; Matysiak-Klose D; Braun V; Leidl R
Z Gastroenterol; 2003 Jun; 41(6):527-36. PubMed ID: 12806538
[TBL] [Abstract][Full Text] [Related]
3. Cost of outpatient care in patients with inflammatory bowel disease in a German University Hospital.
Ebinger M; Leidl R; Thomas S; Von Tirpitz C; Reinshagen M; Adler G; Konig HH
J Gastroenterol Hepatol; 2004 Feb; 19(2):192-9. PubMed ID: 14731130
[TBL] [Abstract][Full Text] [Related]
4. [Cost measurement based on a cost diary in patients with inflammatory bowel disease].
Rösch M; Leidl R; Tirpitz Cv; Reinshagen M; Adler G; König HH
Z Gastroenterol; 2002 Apr; 40(4):217-28. PubMed ID: 11961730
[TBL] [Abstract][Full Text] [Related]
5. Systematic analysis of annual health resource utilization and costs in hospitalized patients with inflammatory bowel disease in Switzerland.
Schoepfer A; Vavricka SR; Brüngger B; Reich O; Blozik E; Bähler C
Eur J Gastroenterol Hepatol; 2018 Aug; 30(8):868-875. PubMed ID: 29757772
[TBL] [Abstract][Full Text] [Related]
6. [Cost of general medical care of patients suffering from chronic inflammatory bowel disease].
Bokemeyer B
Z Gastroenterol; 2003 Sep; 41(9):963-4. PubMed ID: 13130334
[No Abstract] [Full Text] [Related]
7. Healthcare costs of inflammatory bowel disease have shifted from hospitalisation and surgery towards anti-TNFα therapy: results from the COIN study.
van der Valk ME; Mangen MJ; Leenders M; Dijkstra G; van Bodegraven AA; Fidder HH; de Jong DJ; Pierik M; van der Woude CJ; Romberg-Camps MJ; Clemens CH; Jansen JM; Mahmmod N; van de Meeberg PC; van der Meulen-de Jong AE; Ponsioen CY; Bolwerk CJ; Vermeijden JR; Siersema PD; van Oijen MG; Oldenburg B;
Gut; 2014 Jan; 63(1):72-9. PubMed ID: 23135759
[TBL] [Abstract][Full Text] [Related]
8. [Costs of ulcerative colitis within the German Statutory Health Insurance].
Prenzler A; Bokemeyer B; Mittendorf T; von der Schulenburg JM
Dtsch Med Wochenschr; 2010 Feb; 135(7):281-6. PubMed ID: 20146156
[TBL] [Abstract][Full Text] [Related]
9. Non-drug costs associated with outpatient infliximab administration in pediatric inflammatory bowel disease.
Wu M; Sin A; Nishioka F; Park KT
Inflamm Bowel Dis; 2013 Jun; 19(7):1514-7. PubMed ID: 23567783
[TBL] [Abstract][Full Text] [Related]
10. Effect of Standardized Infliximab Dose Rounding on an Outpatient Infusion Center.
Park JJ; Boutillier L; Cruz JE; Joung G; Nemeth J
J Manag Care Spec Pharm; 2018 Oct; 24(10):1028-1033. PubMed ID: 30247103
[TBL] [Abstract][Full Text] [Related]
11. Cost of pain medication to treat adult patients with nonmalignant chronic pain in the United States.
Rasu RS; Vouthy K; Crowl AN; Stegeman AE; Fikru B; Bawa WA; Knell ME
J Manag Care Spec Pharm; 2014 Sep; 20(9):921-8. PubMed ID: 25166291
[TBL] [Abstract][Full Text] [Related]
12. Medical management of inflammatory bowel disease in the new millennium.
Lombardi DA; Feller ER; Shah SA
Compr Ther; 2002; 28(1):39-49. PubMed ID: 11894442
[TBL] [Abstract][Full Text] [Related]
13. Health care resource use and costs in Crohn's disease before and after infliximab therapy.
Loomes DE; Teshima C; Jacobs P; Fedorak RN
Can J Gastroenterol; 2011 Sep; 25(9):497-502. PubMed ID: 21912761
[TBL] [Abstract][Full Text] [Related]
14. Estimating resource use and cost of prophylactic management of neutropenia with filgrastim.
Annemans L; Van Overbeke N; Standaert B; Van Belle S
J Nurs Manag; 2005 May; 13(3):265-74. PubMed ID: 15819840
[TBL] [Abstract][Full Text] [Related]
15. Health Care Cost for Children Newly Diagnosed With Inflammatory Bowel Disease.
Fondell AW; Mosha MH; Frank CR; Brangi JM; Hyams JS
Inflamm Bowel Dis; 2020 Mar; 26(4):635-640. PubMed ID: 31504513
[TBL] [Abstract][Full Text] [Related]
16. Crohn's disease and ulcerative colitis. Occurrence, course and prognosis during the first year of disease in a European population-based inception cohort.
Burisch J
Dan Med J; 2014 Jan; 61(1):B4778. PubMed ID: 24393595
[TBL] [Abstract][Full Text] [Related]
17. Clinical status, psychosocial impairments, medical treatment and health care costs for patients with inflammatory bowel disease (IBD) in Germany: an online IBD registry.
Bokemeyer B; Hardt J; Hüppe D; Prenzler A; Conrad S; Düffelmeyer M; Hartmann P; Hoffstadt M; Klugmann T; Schmidt C; Weismüller J; Mittendorf T; Raspe H
J Crohns Colitis; 2013 Jun; 7(5):355-68. PubMed ID: 22503168
[TBL] [Abstract][Full Text] [Related]
18. Budesonide with multi-matrix technology as second-line treatment for ulcerative colitis: evaluation of long-term cost-effectiveness in the Netherlands.
Gherardi A; Roze S; Kuijvenhoven J; Ghatnekar O; Yip Sonderegger YL
J Med Econ; 2018 Sep; 21(9):869-877. PubMed ID: 29857775
[TBL] [Abstract][Full Text] [Related]
19. Direct hospital costs for patients with inflammatory bowel disease in a Canadian tertiary care university hospital.
Bernstein CN; Papineau N; Zajaczkowski J; Rawsthorne P; Okrusko G; Blanchard JF
Am J Gastroenterol; 2000 Mar; 95(3):677-83. PubMed ID: 10710056
[TBL] [Abstract][Full Text] [Related]
20. Inflammatory bowel disease: medical cost algorithms.
Hay AR; Hay JW
J Clin Gastroenterol; 1992 Jun; 14(4):318-27. PubMed ID: 1607608
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
